Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.

Cancer research - 15 Nov 2004

Ito Fumito, Li Qiao, Shreiner Andrew B, Okuyama Ryuji, Jure-Kunkel Maria N, Teitz-Tennenbaum Seagal, Chang Alfred E

Abstract excerpt

In weakly and poorly immunogenic tumor models, we examined the effects of stimulating CD137 (4-1BB) in vivo by administering anti-CD137 monoclonal antibody after tumor lysate-pulsed dendritic cell (TP-DC) vaccination. TP-DC subcutaneous vaccination induced a transient up-regulation of CD137 on T cells and natural killer (NK) cells within vaccine-primed lymph nodes (VPLNs). In established pulmonary and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antigens, CD

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Killer Cells, Natural

Share to Mice, Inbred C57BL

Share to Receptors, Nerve Growth Factor

Share to Receptors, Tumor Necrosis Factor

Share to T-Lymphocytes

Source

Identifiers

PMID: 15548712
DOI: 10.1158/0008-5472.CAN-04-0590

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.PMID 15548712Read ↗

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.Semantic proximity Read ↗

Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapySemantic proximity Read ↗

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy.Semantic proximity Read ↗

Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.Semantic proximity Read ↗

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 AntibodySemantic proximity Read ↗

Tregs constrain CD8 <sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapySemantic proximity Read ↗

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.Semantic proximity Read ↗

Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for CancerSemantic proximity Read ↗

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapySemantic proximity Read ↗

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor ImmunitySemantic proximity Read ↗

Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.Semantic proximity Read ↗

Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.